Pharmacy- Page 34

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020

Pharmacy

The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Roche has

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results

by The FINANCIAL

November 16, 2020

2 mins read

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

The FINANCIAL — Metagenomi, a next generation gene editing company launched by

by The FINANCIAL

November 12, 2020

1 min read

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

The FINANCIAL — On the occasion of the World Health Assembly, the world’s

by The FINANCIAL

November 12, 2020

1 min read

Pharmacy

Abbott Seeks to Terminate Alere Acquisition

The FINANCIAL -- Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substantial loss in Alere's value following the merger agreement.

by The FINANCIAL

December 8, 2016

1 min read

Pharmacy

Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer

The FINANCIAL -- Roche on December 7 announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment

by The FINANCIAL

December 8, 2016

1 min read

Pharmacy

Novartis’ Ultibro Breezhaler improved lung function and COPD symptoms after direct switch from previous treatment

The FINANCIAL -- Novartis on December 8 announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with moderate COPD from their current treatments, including steroid-containing combinations and long-acting bronchodilators, to the dual bronchodilator

by The FINANCIAL

December 8, 2016

1 min read

Pharmacy

Astellas Launches Kiklin Granules, a Treatment for Hyperphosphatemia, in Japan

The FINANCIAL -- Astellas Pharma Inc. announced that it launched Kiklin Granules 86.2% (generic name: bixalomer, “Kiklin Granules”), an additional formulation of Kiklin Capsules 250 mg (“Kiklin Capsules”), for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease (“CKD”)

by The FINANCIAL

December 7, 2016

1 min read

Pharmacy

Novartis’ Lucentis received EU approval in new indication

The FINANCIAL -- Novartis on December 7 announced that the European Commission (EC) has granted an additional indication for Lucentis (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular degeneration (nAMD),

by The FINANCIAL

December 7, 2016

1 min read

Pharmacy

AbbVie and Johns Hopkins to Collaborate on Cancer Research

The FINANCIAL -- AbbVie and the Johns Hopkins University School of Medicine on December 5 announced that they signed a five-year collaboration agreement with the goal of advancing medical oncology research and discovery at both organizations.

by The FINANCIAL

December 6, 2016

1 min read

Pharmacy

Teva Receives Positive Outcome for COPAXONE Label in Europe

The FINANCIAL -- Teva Pharmaceutical Industries Ltd. on December 6 announced that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE (glatiramer acetate injection) 20 mg/mL.

by The FINANCIAL

December 6, 2016

1 min read

Pharmacy

U.S. FDA approves Jardiance (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes

The FINANCIAL -- The U.S. Food and Drug Administration (FDA) approved a new indication for Jardiance (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

by The FINANCIAL

December 6, 2016

2 mins read

Pharmacy

Novartis: Zykadia More Than Doubles Progression-free Survival In ASCEND-4 Study

The FINANCIAL -- Novartis on December 6 announced results from its Phase III open-label, randomized, active-controlled, multi-center ASCEND-4 study, which found that patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) treated with first-line Zykadia (ceritinib) had a median

by The FINANCIAL

December 6, 2016

2 mins read

Pharmacy

Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF

The FINANCIAL -- On December 5, Pfizer Inc. and its partner Avillion LLP announced results from the Phase 3 BFORE (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment) trial demonstrating superiority of BOSULIF (bosutinib) over imatinib as a first-line treatment for

by The FINANCIAL

December 5, 2016

1 min read